{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T09:19:52Z","timestamp":1788599992234,"version":"build-2803163510"},"reference-count":26,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND AND OBJECTIVES<\/jats:title>\n                  <jats:p>Options to treat and prevent episodic wheezing in children are scarce. Our objective was to assess the efficacy of intermittent tiotropium bromide treatment in early childhood episodic wheezing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>This 48-week, randomized, open-label, controlled, parallel-group trial was conducted at 4 hospitals in Finland. Children aged 6 to 35 months with 2 to 4 physician-confirmed episodes of wheeze and\/or shortness of breath were considered eligible. Study participants were randomly allocated to receive 1 of 3 treatments: once-daily tiotropium bromide 5 \u00b5g for 7 to 14 days during respiratory tract infections and as-needed albuterol sulfate 0.2 mg (n = 27), twice-daily fluticasone propionate 125 \u00b5g for 7 to 14 days during respiratory tract infections and as-needed albuterol sulfate 0.2 mg (n = 25), or as-needed albuterol sulfate 0.2 mg alone (n = 28). The primary outcome was efficacy, assessed as intention-to-treat by comparing the proportion of episode-free days (the days lacking symptoms or treatments) between the treatment groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>The proportion of episode-free days was higher in those receiving intermittent tiotropium bromide (median 97% [interquartile range, 93% to 99%]) than in those receiving intermittent fluticasone propionate (87% [78% to 93%], P = .002), or with as-needed albuterol sulfate alone (88% [79% to 95%], P = .003). Adjustment with allergic sensitization, the baseline number of physician-confirmed episodes of wheeze and\/or shortness of breath, or short-course glucocorticoid treatment in the 2 weeks before the enrollment, did not affect the result. Intervention-related adverse events were not seen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Intermittent tiotropium bromide treatment may be an effective alternative to current therapies for episodic wheezing. Before implementation of use, further research on safety and efficacy is indicated.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2021-055860","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T08:17:47Z","timestamp":1660033067000},"source":"Crossref","is-referenced-by-count":9,"title":["Intermittent Tiotropium Bromide for Episodic Wheezing: A Randomized Trial"],"prefix":"10.1542","volume":"150","author":[{"given":"Anne","family":"Kotaniemi-Syrj\u00e4nen","sequence":"first","affiliation":[{"name":"aHUS Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Klemola","sequence":"additional","affiliation":[{"name":"bHUS Jorvi Hospital, Espoo, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petri","family":"Koponen","sequence":"additional","affiliation":[{"name":"cHUS Hyvink\u00e4\u00e4 Hospital, Hyvink\u00e4\u00e4, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Outi","family":"Jauhola","sequence":"additional","affiliation":[{"name":"cHUS Hyvink\u00e4\u00e4 Hospital, Hyvink\u00e4\u00e4, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrikka","family":"Aito","sequence":"additional","affiliation":[{"name":"dHUS Porvoo Hospital, Porvoo, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristiina","family":"Malmstr\u00f6m","sequence":"additional","affiliation":[{"name":"aHUS Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Pekka","family":"Malmberg","sequence":"additional","affiliation":[{"name":"aHUS Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eero","family":"Rahiala","sequence":"additional","affiliation":[{"name":"eHUS Children\u2019s Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seppo","family":"Sarna","sequence":"additional","affiliation":[{"name":"fUniversity of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna S.","family":"Pelkonen","sequence":"additional","affiliation":[{"name":"aHUS Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika J.","family":"M\u00e4kel\u00e4","sequence":"additional","affiliation":[{"name":"aHUS Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"issue":"2","key":"2023110816292652900_B1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jaci.2012.04.043","article-title":"\u201cTo wheeze or not to wheeze\u201d: that is not the question","volume":"130","author":"Skytt","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"2023110816292652900_B2","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1164\/rccm.200410-1404OC","article-title":"Airway remodeling and inflammation in symptomatic infants with reversible airflow obstruction","volume":"171","author":"Saglani","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"21","key":"2023110816292652900_B3","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.2174\/1381612811209023061","article-title":"Treatment of disorders characterized by reversible airway obstruction in childhood: are anti-cholinergic agents the answer?","volume":"18","author":"Quizon","year":"2012","journal-title":"Curr Pharm Des"},{"issue":"6","key":"2023110816292652900_B4","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaci.2020.10.003","article-title":"2020 focused updates to the asthma management guidelines: a report from the national asthma education and prevention program coordinating committee expert panel working group","volume":"146","author":"Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC)","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2023110816292652900_B5","unstructured":"Global Initiative for Asthma; GINA reports\n          . Global strategy for asthma management and prevention, 2021. Available at: https:\/\/ginasthma.org\/wp-content\/uploads\/2021\/05\/GINA-Main-Report-2021-V2-WMS.pdf. Accessed February 22, 2021"},{"issue":"3","key":"2023110816292652900_B6","first-page":"CD002873","article-title":"Short acting beta agonists for recurrent wheeze in children under 2 years of age","volume":"2002","author":"Chavasse","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2023110816292652900_B7","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jpeds.2004.04.007","article-title":"\u03b2-agonists through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: a systematic review with meta-analysis","volume":"145","author":"Castro-Rodriguez","year":"2004","journal-title":"J Pediatr"},{"issue":"2","key":"2023110816292652900_B8","first-page":"CD001107","article-title":"Inhaled steroids for episodic viral wheeze of childhood","volume":"2000","author":"McKean","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2023110816292652900_B9","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.jaci.2008.09.029","article-title":"Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing","volume":"122","author":"Bacharier","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"21","key":"2023110816292652900_B10","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1056\/NEJMoa1104647","article-title":"Daily or intermittent budesonide in preschool children with recurrent wheezing","volume":"365","author":"Zeiger","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"2023110816292652900_B11","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJMoa1203229","article-title":"Effect of inhaled glucocorticoids in childhood on adult height","volume":"367","author":"Kelly","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"2023110816292652900_B12","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S2213-2600(14)70186-9","article-title":"Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo-controlled trial","volume":"2","author":"Nwokoro","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"2","key":"2023110816292652900_B13","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1378\/chest.14-1698","article-title":"What is the role of tiotropium in asthma?: a systematic review with meta-analysis","volume":"147","author":"Rodrigo","year":"2015","journal-title":"Chest"},{"issue":"2","key":"2023110816292652900_B14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jaci.2016.01.011","article-title":"Tiotropium add-on therapy in adolescents with moderate asthma: a 1-year randomized controlled trial","volume":"138","author":"Hamelmann","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2023110816292652900_B15","doi-asserted-by":"crossref","first-page":"1601100","DOI":"10.1183\/13993003.01100-2016","article-title":"A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma","volume":"49","author":"Hamelmann","year":"2017","journal-title":"Eur Respir J"},{"issue":"9","key":"2023110816292652900_B16","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.rmed.2014.06.011","article-title":"Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study","volume":"108","author":"Vogelberg","year":"2014","journal-title":"Respir Med"},{"issue":"1","key":"2023110816292652900_B17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12931-015-0175-9","article-title":"A randomised dose-ranging study of tiotropium Respimat\u00ae in children with symptomatic asthma despite inhaled corticosteroids","volume":"16","author":"Vogelberg","year":"2015","journal-title":"Respir Res"},{"issue":"5","key":"2023110816292652900_B18","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jaci.2017.01.014","article-title":"A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma","volume":"140","author":"Szefler","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2023110816292652900_B19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S2213-2600(18)30012-2","article-title":"Safety and efficacy of tiotropium in children aged 1-5 years with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial","volume":"6","author":"Vrijlandt","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"6","key":"2023110816292652900_B20","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.jaip.2018.04.032","article-title":"Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma","volume":"6","author":"Vogelberg","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"2023110816292652900_B21","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1542\/peds.111.3.e255","article-title":"Allergen-specific immunoglobulin E antibodies in wheezing infants: the risk for asthma in later childhood","volume":"111","author":"Kotaniemi-Syrj\u00e4nen","year":"2003","journal-title":"Pediatrics"},{"issue":"19","key":"2023110816292652900_B22","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1056\/NEJMoa051378","article-title":"Long-term inhaled corticosteroids in preschool children at high risk for asthma","volume":"354","author":"Guilbert","year":"2006","journal-title":"N Engl J Med"},{"issue":"19","key":"2023110816292652900_B23","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1056\/NEJMoa054692","article-title":"Intermittent inhaled corticosteroids in infants with episodic wheezing","volume":"354","author":"Bisgaard","year":"2006","journal-title":"N Engl J Med"},{"issue":"7","key":"2023110816292652900_B24","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.jaip.2019.03.019","article-title":"Tiotropium is efficacious in 6- to 17-year-olds with asthma, independent of T2 phenotype","volume":"7","author":"Szefler","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"2023110816292652900_B25","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jaip.2018.01.016","article-title":"Tiotropium attenuates refractory cough and capsaicin cough reflex sensitivity in patients with asthma","volume":"6","author":"Fukumitsu","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"2023110816292652900_B26","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaci.2004.09.020","article-title":"Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma","volume":"114","author":"Guilbert","year":"2004","journal-title":"J Allergy Clin Immunol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2021-055860\/1561253\/peds_2021055860.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2021-055860\/1561253\/peds_2021055860.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T16:32:29Z","timestamp":1699461149000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/150\/3\/e2021055860\/188736\/Intermittent-Tiotropium-Bromide-for-Episodic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,8,9]]},"published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2021-055860","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,9]]},"article-number":"e2021055860"}}